These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 32201163)

  • 21. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.
    Hu J; Fung MW; Tsang JY; Poon IK; Chan SK; Cheung SY; Hu H; Zhou D; Tse GM
    Clin Breast Cancer; 2020 Jun; 20(3):253-261.e7. PubMed ID: 32205037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
    Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
    Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer.
    Cuello-López J; Fidalgo-Zapata A; López-Agudelo L; Vásquez-Trespalacios E
    PLoS One; 2018; 13(11):e0207224. PubMed ID: 30427884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients' survival.
    Choi H; Noh H; Cho IJ; Lim ST; Han A
    Breast Cancer; 2020 Sep; 27(5):871-879. PubMed ID: 32221862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
    Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
    Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.
    Chen XS; Wu JY; Huang O; Chen CM; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Oncol Rep; 2010 May; 23(5):1213-20. PubMed ID: 20372832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer.
    von Au A; Shencoru S; Uhlmann L; Mayer L; Michel L; Wallwiener M; Hennigs A; Deutsch T; Riedel F; Heil J; Golatta M; Schneeweiss A; Schütz F; Domschke C
    Arch Gynecol Obstet; 2023 Apr; 307(4):1105-1113. PubMed ID: 35980458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
    BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
    Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
    Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting.
    Koh YW; Lee HJ; Ahn JH; Lee JW; Gong G
    Tumour Biol; 2014 Oct; 35(10):9823-30. PubMed ID: 24986572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Du Q; Che J; Jiang X; Li L; Luo X; Li Q
    Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
    Sinn BV; Sychra K; Untch M; Karn T; van Mackelenbergh M; Huober J; Schmitt W; Marmé F; Schem C; Solbach C; Stickeler E; Tesch H; Fasching PA; Schneeweiss A; Müller V; Holtschmidt J; Nekljudova V; Loibl S; Denkert C
    Breast Cancer Res; 2024 Sep; 26(1):138. PubMed ID: 39317942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients.
    Peng Y; Chen R; Qu F; Ye Y; Fu Y; Tang Z; Wang Y; Zong B; Yu H; Luo F; Liu S
    Cancer Biol Ther; 2020; 21(2):189-196. PubMed ID: 31684807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of outcomes after chemoradiotherapy for cervical cancer by neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio.
    Yu J; Huang L; Dong T; Cao L
    J Obstet Gynaecol; 2024 Dec; 44(1):2361858. PubMed ID: 38864403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.